233 | S1608: RANDOMIZED PHASE II TRIAL COMPARING LENALIDOMIDE/OBINUTUZUMAB AND UMBRALISIB/OBINUTUZUMAB WITH CHEMOIMMUNOTHERAPY IN EARLY PROGRESSING FOLLICULAR LYMPHOMA (POD24)
Hematological Oncology · 2025-06 · 43 (S3)
DOI: 10.1002/hon.70094_233 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 16.06.2025. Verfasst von P. M. Barr und 14 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Barr, P. M., Li, H., Schoder, H., Herrera, A. F., Burack, W. R., Link, B. K., Flowers, C. R., Weigert, O., Casulo, C., Siddiqi, T., Venugopal, P., Leonard, J. P., Kahl, B. S., Smith, S. M., & Friedberg, J. W. (2025). 233 | S1608: RANDOMIZED PHASE II TRIAL COMPARING LENALIDOMIDE/OBINUTUZUMAB AND UMBRALISIB/OBINUTUZUMAB WITH CHEMOIMMUNOTHERAPY IN EARLY PROGRESSING FOLLICULAR LYMPHOMA (POD24). Hematological Oncology, 43(S3). https://doi.org/10.1002/hon.70094_233
Vancouver
Barr PM, Li H, Schoder H, Herrera AF, Burack WR, Link BK, et al. 233 | S1608: RANDOMIZED PHASE II TRIAL COMPARING LENALIDOMIDE/OBINUTUZUMAB AND UMBRALISIB/OBINUTUZUMAB WITH CHEMOIMMUNOTHERAPY IN EARLY PROGRESSING FOLLICULAR LYMPHOMA (POD24). Hematological Oncology. 2025;43(S3). doi:10.1002/hon.70094_233
BibTeX
@article{Barr2025,
author = {Barr, P. M. and Li, H. and Schoder, H. and Herrera, A. F. and Burack, W. R. and Link, B. K. and Flowers, C. R. and Weigert, O. and Casulo, C. and Siddiqi, T. and Venugopal, P. and Leonard, J. P. and Kahl, B. S. and Smith, S. M. and Friedberg, J. W.},
title = {233 | S1608: RANDOMIZED PHASE II TRIAL COMPARING LENALIDOMIDE/OBINUTUZUMAB AND UMBRALISIB/OBINUTUZUMAB WITH CHEMOIMMUNOTHERAPY IN EARLY PROGRESSING FOLLICULAR LYMPHOMA (POD24)},
journal = {Hematological Oncology},
year = {2025},
volume = {43},
number = {S3},
doi = {10.1002/hon.70094_233}
}
EUVIMED